Nachrichten zur Gilead Sciences Inc. Aktie

Gilead Sciences Aktie: HIV-Hoffnung Yeztugo im Fokus - Outperform-Rating bekräftigt

New York (www.aktiencheck.de) - Gilead-Aktienanalyse von Oppenheimer: Die Analysten von Oppenheimer haben das Rating "outperform" für die Aktie von Gilead Sciences…

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences Aktie: "Großer Sieg! durch Yeztugo-Zulassung!

Toronto (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von BMO Capital Markets: Wenn es nach den Analysten von BMO Capital Marktes gehe, dann habe…

Gilead Sciences Aktie: Deutlicher Optimismus!

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Mizuho Securities USA: Nach der FDA-Zulassung des injizierbaren HIV-1-Capsid-Hemmers Yeztugo (Lenacapavir) habe das Analysehaus…

Gilead Sciences Aktie: Startschuss für Yeztugo - "Erwarteter Turbo“ für die Aktie!

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Morgan Stanley: Die Genehmigung durch die US-Arzneimittelbehörde FDA könnte als wichtiger Meilenstein für Gilead…

Gilead Sciences: Zulassung für HIV-Prophylaxe mit Gamechanger-Potenzial - News verpuffen

Gilead Sciences hat die vom Markt erwartete Marktzulassung für seine neuartige HIV-Präventionstherapie Lenacapavir von der FDA erhalten. Doch wie gewonnen,…

Gilead Sciences: Zulassung für HIV-Prophylaxe mit Gamechanger-Potenzial – News verpuffen

Gilead Sciences hat die vom Markt erwartete Marktzulassung für seine neuartige HIV-Präventionstherapie Lenacapavir von der FDA erhalten. Doch wie gewonnen,…

Gilead Sciences: Zulassung für HIV-Prophylaxe mit Gamechanger-Potenzial – News verpuffen

Gilead Sciences hat die vom Markt erwartete Marktzulassung für seine neuartige HIV-Präventionstherapie Lenacapavir von der FDA erhalten. Doch wie gewonnen,…

Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)’s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being…

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

…

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware…

Why Gilead Scinces Stock Tumbled on Tuesday

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took…

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

…

Gilead Sciences shares hit after HIV studies placed on hold by FDA By Investing.com

Gilead Sciences shares hit after HIV studies placed on hold by FDA…

Gilead shares fall after FDA places clinical hold on HIV treatment trials

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug…

Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)

…

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend…

Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

…

Gilead Sciences Best Days May Be Ahead - Heres Why

…

Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)

…

Heres Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a…

Gilead Sciences Aktie: 140 oder 93 USD? Kursziele und Ratings der Analysten nach Q1-Zahlen auf einen Blick - Aktiennews

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

Disney, Gilead Sciences, Eaton and Maui Land & Pineapple are included in this Analyst Blog.…

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but…

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

Todays Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences, Inc.…

Gilead announces $11 billion in new investments in US

Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned…

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors By Reuters

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors…

Why Gilead Sciences Stock Slipped Today

Gilead Sciences (NASDAQ: GILD) didnt have a bad first quarter, but investors didnt find it inspiring either. After publishing its…

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Gilead Sciences Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.…

Gilead (GILD) Q1 2025 Earnings Call Transcript

Image source: The Motley Fool. DATEThursday, Apr 24, 2025CALL PARTICIPANTSDaniel ODay: Chairman and Chief Executive OfficerJohanna Mercier: Chief Commercial OfficerDietmar Berger:…

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the…

Gilead Sciences shares fall as Q1 revenue misses estimates By Investing.com

Gilead Sciences shares fall as Q1 revenue misses estimates…

Gilead reports quarterly profit, revenue flat as cancer sales slow

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of drugs for HIV and…

Interessante Einstiege finden - BioNTech, BioNxt Solutions, Gilead Sciences, Merck & Co.

Die aggressive Zollpolitik der US-Administration unter US-Präsident Trump hat zu Umschichtungsprozessen bei den Anlegern geführt. So zogen europäische ETF-Anleger über…

Heres Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Gilead Sciences leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be…

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.…

Is Iovance Biotherapeutics a Millionaire-Maker?

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up…

Rule Breaker Investing: Essays From Yesterday, Vol. 7

Its time once again to dust off Motley Fool co-founder David Gardners old writings and pull some lessons forward into…

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the…

2 Top Dividend Stocks That Could Set You Up for Life

With equity markets in shambles due to President Donald Trumps trade policies, now might be as good a time as…

Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex…

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its…

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading…

Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.…

Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the…

GILD Stock Down on Report of Cut in HIV Prevention Spending

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash…